$1.48-0.51 (-25.63%)
Codexis, Inc.
Codexis, Inc. in the Healthcare sector is trading at $1.48 with a market capitalization of $227M. Wall Street consensus targets $6.58 (6 analysts), implying a +344.8% move over the next 12 months. The stock is currently near its 52-week low of $0.96, remaining 26.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 11 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.25Mβ | $38.91Mβ | $8.60Mβ | $15.33Mβ | $7.54M |
| Gross Profit | $13.18Mβ | $36.87Mβ | $6.14Mβ | $13.23Mβ | $4.81M |
| Operating Income | -$8.04Mβ | $13.97Mβ | -$18.95Mβ | -$12.86Mβ | -$20.49M |
| Net Income | -$8.70Mβ | $9.60Mβ | -$19.61Mβ | -$13.27Mβ | -$20.69M |
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe,...
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.
A week ago, Codexis, Inc. ( NASDAQ:CDXS ) came out with a strong set of first-quarter numbers that could potentially...
Need a quote from a Motley Fool analyst? Alison Moore: Thank you, Georgia, and thanks, everyone, for joining. While it's been a short 8 weeks since our last call, we've accomplished a lot at Codexis.
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
Codexis (CDXS) delivered earnings and revenue surprises of +9.09% and +1.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?